PPARδ/γ agonist 1 sodium

Cat. No.: HY-120596

CAS No.: 1258076-66-2

Molecular Formula: $C_{25}H_{26}NNaO_5$

Molecular Weight: 443.47

Target: PPAR

Pathway: Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (112.75 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2549 mL	11.2747 mL	22.5494 mL
	5 mM	0.4510 mL	2.2549 mL	4.5099 mL
	10 mM	0.2255 mL	1.1275 mL	2.2549 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PPARδ/γ agonist 1 sodium is a chemically unique and brain penetrant dual PPAR delta/gamma agonist. PPARδ/γ agonist 1 sodium can be used for the research of Alzheimer's disease[1].

In Vivo

PPARδ/γ agonist 1 sodium (1 mg/kg; i.g. once daily for 16 days) restores STZ-mediated impairments of motor function[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	STZ-mediated Long Evans rats[1]
Dosage:	1 mg/kg

Administration:	Oral gavage; 1 mg/kg once daily, for 16 days
Result:	Improved performance in STZ-mediated rats and showed neuroprotective for both granule and Purkinje cells.

REFERENCES

[1]. Tong M, et al. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA